Author: jnajera2

Despite unstinting interventions such as chemotherapy and surgical tumor removal, approximately 40% of patients with stage I-III triple-negative breast cancer (TNBC) will experience tumor recurrence. Fortunately, not all hope is lost. The advent of immune checkpoint blockade (ICB) immunotherapy—a type of therapy that uses one’s own immune cells to kill the cancer—has shown great promise for the treatment of TNBC. However, as Dr. Azra Raza says in her book, The First Cell: And the Human Costs of Pursuing Cancer to the Last, these “immune approaches are not universally curative and, at present, help very few patients.”